

Queensland



Drugs Misuse Act 1986

DRUGS MISUSE REGULATION 1987

**Reprinted as in force on 14 August 1998
(includes amendments up to SL No. 459 of 1998)**

Reprint No. 2B

**This reprint is prepared by
the Office of the Queensland Parliamentary Counsel
Warning—This reprint is not an authorised copy**

Information about this reprint

This regulation is reprinted as at 14 August 1998. The reprint shows the law as amended by all amendments that commenced on or before that day (Reprints Act 1992 s 5(c)).

The reprint includes a reference to the law by which each amendment was made—see list of legislation and list of annotations in endnotes.

This page is specific to this reprint. See previous reprints for information about earlier changes made under the Reprints Act 1992. A table of earlier reprints is included in the endnotes.

Also see endnotes for information about—

- **when provisions commenced**
- **editorial changes made in earlier reprints.**

Queensland



DRUGS MISUSE REGULATION 1987

TABLE OF PROVISIONS

Section		Page
PART 1—PRELIMINARY		
1	Short title	3
4	Definitions	3
PART 2—SEARCH WARRANT NOTICES AND RECORD		
5	Notice to justice before whom a complaint to ground a search warrant is to be sworn	3
6	Record of proceedings	4
7	Notice to occupier of place entered pursuant to warrant	4
PART 3—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES		
9	Prescribed procedures for the disposal of hypodermic syringes and needles	5
10	Prescribed procedure for disposal of dangerous drugs	5
PART 4—CONTROLLED SUBSTANCES		
11	Other act that is a relevant transaction—Act, s 43C(b)	6
12	Documents and proof of identity required for supply of a controlled substance—Act, s 43D(1)(a)	6
13	Details about supply of controlled substance to be recorded in register ...	7
14	Details about loss or theft of controlled substance to be recorded in register	8
15	Keeping of register, invoice and other documents	8
SCHEDULE 1		
DANGEROUS DRUGS		
SCHEDULE 2		
DANGEROUS DRUGS		

	SCHEDULE 3	18
	SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS	
	SCHEDULE 4	20
	SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS	
	SCHEDULE 5	21
	DANGEROUS DRUGS	
	SCHEDULE 6	24
	CONTROLLED SUBSTANCES	
	ENDNOTES	
1	Index to endnotes	25
2	Date to which amendments incorporated	25
3	Key	25
4	Table of earlier reprints	26
5	List of legislation	26
6	List of annotations	27

DRUGS MISUSE REGULATION 1987

[as amended by all amendments that commenced on or before 14 August 1998]

PART 1—PRELIMINARY

Short title

1. This regulation may be cited as the *Drugs Misuse Regulation 1987*.

Definitions

4. In this regulation—

“**occupier’s notice**” means an occupier’s notice referred to in section 7.

“**record of proceedings**” means a record of proceedings referred to in section 6.

“**search warrant**” means a search warrant issued under section 18 of the Act.

“**supply**” see section 43A¹ of the Act.

PART 2—SEARCH WARRANT NOTICES AND RECORD

Notice to justice before whom a complaint to ground a search warrant is to be sworn

5. A justice of the peace (other than a stipendiary magistrate) who has before him or her a complaint to ground a search warrant shall be given a

¹ Section 43A (Definitions)

notice in the approved form by the complainant and shall read such notice prior to administering an oath for the purposes of such complaint.

Record of proceedings

6.(1) A justice of the peace who has a complaint sworn before him or her to ground a search warrant shall cause a record to be made of such proceedings in the approved form.

(2) The justice of the peace shall retain or cause to be retained by the nearest clerk of the court the complaint to ground a search warrant and record of proceedings for 2 years or such longer period as may be required in the particular case.

Notice to occupier of place entered pursuant to warrant

7.(1) A police officer to whom a search warrant has been issued shall prepare an occupier's notice in the approved form.

(2) A police officer executing a search warrant shall—

- (a)** upon entry into or on the place to which the warrant relates, or at the first reasonable opportunity thereafter, serve the occupier's notice on a person who appears to be an occupier of that place; and
- (b)** if no such person is then present, or if service is not practicable for any other reason, serve the occupier's notice by leaving it in a conspicuous location in or on that place.

(3) Subsection (2) does not apply where the police officer executing a search warrant has reasonable grounds to believe that service of an occupier's notice would frustrate or otherwise hinder the investigation of the offence in respect of which the search warrant was issued.

PART 3—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES

Prescribed procedures for the disposal of hypodermic syringes and needles

9. For the purposes of section 10(4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle shall be as follows—

- (a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or
- (b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10(3) of the Act.

Prescribed procedure for disposal of dangerous drugs

10. For the purposes of section 52A of the Act, the prescribed procedure for the disposal of a thing shall be as follows—

- (a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 9; or
- (b) in any other case, at the first reasonable opportunity, by giving—
 - (i) such thing; and
 - (ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;

to an officer authorised to exercise the powers contained in the *Health Act 1937*, section 132.

PART 4—CONTROLLED SUBSTANCES

Other act that is a relevant transaction—Act, s 43C(b)

11. Any act by which a controlled substance is supplied² by a person, in or in connection with the person's business, to anyone else is a relevant transaction for the supply of a controlled substance.

Example—

A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances.

The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away.

Both the sale and gift of ephedrine are relevant transactions.

Documents and proof of identity required for supply of a controlled substance—Act, s 43D(1)(a)

12.(1) This section applies to a person who supplies a controlled substance under a relevant transaction to anyone else (a “**recipient**”).

(2) The person must, before supplying the substance, obtain from the recipient a written order for the supply of the substance showing the following information—

- (a) the recipient's name and address, and if the recipient purports to obtain the substance for another person, the other person's name and address;
- (b) the date and number of the order;
- (c) the name and quantity of the substance to be supplied;
- (d) the purpose for which the substance is to be supplied.

(3) If the recipient is an individual, the person must, before supplying the substance, require the recipient to produce an official document containing the recipient's photograph (for example, a passport or drivers licence) as evidence of the recipient's identity.

² Under section 43A of the Act, “supply” means give, distribute, sell or supply.

(4) The person must, immediately the person supplies the substance under the transaction, make an invoice for the supply of the substance showing the following details—

- (a) the recipient's name and address;
- (b) the recipient's order number for the supply of the substance;
- (c) the date the substance was supplied;
- (d) the name and quantity of the substance supplied.

Maximum penalty for subsection (4)—20 penalty units.

Details about supply of controlled substance to be recorded in register

13.(1) The following details about a relevant transaction for the supply of a controlled substance must be recorded in the register³—

- (a) the name and address of the recipient and, if the recipient purports to obtain the substance for another person, the other person's name and address;
- (b) the recipient's order number for the supply of the substance;
- (c) the invoice number for the supply of the substance;
- (d) if the recipient is—
 - (i) a company—its Australian Company Number; or
 - (ii) an individual—the type of official document produced under section 12(3) and the following details about the document—
 - (A) who issued it;
 - (B) its serial number or other identifying number or mark;
- (e) the name and quantity of the substance supplied;
- (f) the date the substance was supplied;
- (g) the purpose for which the substance was supplied.

(2) The details must be recorded in the register as soon as practicable, but

³ See section 43D(1)(c) of the Act for the requirement to keep the register.

in no case later than 7 days, after the day the person supplied the substance under the transaction.

(3) Nothing in this section prevents the keeping of a single register for the Act and another Act if—

- (a) the keeping of the single register is not contrary to the other Act; and
- (b) the details recorded under subsection (1) are easily identifiable in the single register.

Details about loss or theft of controlled substance to be recorded in register

14. The following details of the reporting to a police officer of the loss or theft of a controlled substance must be recorded in the register—

- (a) the day and place the report was made;
- (b) the name and registered number of the officer to whom the report was made;
- (c) the name and quantity of the substance lost or stolen.

Keeping of register, invoice and other documents

15.(1) This section applies to the register and other documents mentioned in the Act, section 43D(1) and the invoice required under section 12(4).

(2) A person who supplies a controlled substance under a relevant transaction must keep the register, documents or invoice—

- (a) at the principal or only place in Queensland where the person engages in relevant transactions; and
- (b) for 2 years from the day the person supplied the substance under the transaction.

SCHEDULE 1

DANGEROUS DRUGS

sections 4, 5, 6, 8, 8A, 9 and 59 of the Act

Cocaine

Heroin

Lysergide

Phencyclidine

SCHEDULE 2**DANGEROUS DRUGS**

sections 4, 5, 6, 8, 8A, 9 and 59 of the Act

Acetorphine

Acetyldihydrocodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of acetyldihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine

Acetylmethadol

Acetylmorphines

Alfentanil

Alkoxyamphetamines and bromo-substituted alkoxyamphetamines except where separately specified

Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines except where separately specified

Allylprodine

Alphacetylmethadol

Alphameprodine

Alphamethadol

Alphaprodine

Amphetamine

Anileridine

SCHEDULE 2 (continued)

Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring

Benzethidine

Benzylmorphine

Betacetylmethadol

Betameprodine

Betamethadol

Betaprodine

Bezitramide

4-Bromo-2,5-dimethoxyamphetamine

4-Bromo-2,5-dimethoxyphenethylamine

Bufotenine

Buprenorphine

Cannabinoids except tetrahydrocannabinols

Cannabis sativa

Clonitazene

Coca leaf

Codeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine

Codeine-N-oxide

Codoxime

4-Cyano-1-Methyl-4-Phenylpiperidine

4-Cyano-2-Dimethylamino-4,4-Diphenylbutane

SCHEDULE 2 (continued)

Desomorphine

Diampromide

Diethylthiambutene

N,N-Diethyltryptamine

Difenoxin except in preparations containing 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine

Dihydromorphine

Dimenoxadol

Dimepheptanol

2,5-Dimethoxyamphetamine

2,5-Dimethoxy-4-Ethylamphetamine (DOET)

2,5-Dimethoxy-4-Methylamphetamine

Dimethylamino-1,2-Diphenylethane

3-(1,2-Dimethylheptyl)-1-Hydroxy-7,8,9,10-Tetrahydro-6,6,9-Trimethyl-6 H-Dibenzo(b,d)Pyran

Dimethylthiambutene

N,N-Dimethyltryptamine

Dioxaphetyl butyrate

Diphenoxylate except in preparations containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

SCHEDULE 2 (continued)

Dipipanone

Drotebanol

Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine

Ethylmethylthiambutene

Ethylmorphine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of ethylmorphine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of ethylmorphine

N-Ethyl-1-Phencyclohexylamine

Etonitazine

Etorphine

Etoxeridine

Fenethylamine

Fentanyl

Furethidine

Gamma hydroxybutyric acid

Hydrocodone

Hydromorphanol

Hydromorphone

Hydroxypethidine

Isomethadone

Ketamine

Ketobemidone

Levophenacymorphan

SCHEDULE 2 (continued)

Lysergamide and N-alkyl derivatives of lysergamide other than lysergide

Lysergic acid

Mecloqualone

Mescaline (3,4,5-Trimethoxyphenethylamine)

Metazocine

Methadone

Methaqualone

Methcathinone

5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)

Methylamphetamine

Methylodesorphine

Methyldihydromorphine

3,4-Methylenedioxyamphetamine

3,4-methylenedioxyethylamphetamine (MDEA)

3,4-Methylenedioxymethamphetamine (MDMA)

2-Methyl-3-Morpholino-1, 1-Diphenylpropane Carboxylic acid

Methylphenidate

1-Methyl-4-Phenylpiperidine-4-Carboxylic acid

Metopon

Moramide

Morpheridine

Morphine

Morphine methobromide

Morphine-N-oxide

Myrophine

Nabilone

SCHEDULE 2 (continued)

Nicocodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicocodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicocodine

Nicodicodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicodicodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicodicodine

Nicomorphine

Noracymethadol

Norcodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of norcodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of norcodeine

Norlevorphanol

Normethadone

Normorphine

Norpipanone

Opium

Oxycodone

Oxymorphone

Papaver orientale

Papaver setigerum

SCHEDULE 2 (continued)

Papaver somniferum L. except the seed thereof which seed has been rendered sterile

Parahexyl

Paramethoxyamphetamine (PMA)

Pentazocine

Pethidine

Phenadoxone

Phenampromide

Phenazocine

Phendimetrazine

Phenmetrazine

Phenomorphane

Phenoperidine

1-(1-Phenylcyclohexyl)pyrrolidine

4-Phenylpiperidine-4-Carboxylic acid ethyl ester

Pholcodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine

Piminodine

Piritramide

Proheptazine

Properidine

Propiram

Psilocin

SCHEDULE 2 (continued)

Psilocybin

Racemethorphan

Racemoramide

Racemorphan

Sufentanil

Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids

Thebacon

Thebaine

1-(1-(2-thienyl)cyclohexyl)piperidine

Tilidine

Trimeperidine

3, 4, 5-Trimethoxyamphetamine (TMA)

SCHEDULE 3**SPECIFIED QUANTITIES FOR PARTICULAR
DANGEROUS DRUGS**

sections 4, 8, 9, 52A and 59 of the Act

Dangerous drug	Quantity of dangerous drug
Amphetamine	2.0 g
Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring	50.0 g
4-Bromo-2,5-dimethoxyamphetamine	0.5 g
4-Bromo-2,5-dimethoxyphenethylamine	2.0 g
Cannabis sativa	500.0 g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0 g, 100 plants
Cocaine	2.0 g
Codeine	10.0 g
N,N-Diethyltryptamine	2.0 g
2,5-Dimethoxy-4-Ethylamphetamine (DOET)	2.0 g
2,5-Dimethoxy-4-Methylamphetamine	2.0 g
N,N-Dimethyltryptamine	2.0 g
Fenethylamine	2.0 g

SCHEDULE 3 (continued)

Fentanyl	0.01 g
Gamma hydroxybutyric acid	2.0 g
Heroin	2.0 g
Hydromorphone	2.0 g
Lysergide	0.004 g
Methadone	2.0 g
Methcathinone	2.0 g
5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)	2.0 g
Methylamphetamine	2.0 g
3,4-methylenedioxyethylamphetamine (MDEA)	2.0 g
3,4-Methylenedioxymethamphetamine (MDMA)	2.0 g
Moramide	2.0 g
Morphine	2.0 g
Opium	20.0 g
Paramethoxyamphetamine (PMA)	2.0 g
Pethidine	10.0 g
Phencyclidine	0.5 g
Psilocin	0.10 g
Psilocybin	0.10 g
Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids	2.0 g
3,4,5-Trimethoxyamphetamine (TMA)	2.0 g

SCHEDULE 4**SPECIFIED QUANTITIES FOR PARTICULAR
DANGEROUS DRUGS**

sections 4, 8, 9 and 59 of the Act

Dangerous drug	Quantity of dangerous drug
Cocaine	200.0 g
Heroin	200.0 g
Lysergide	0.4 g
Phencyclidine	50.0 g

SCHEDULE 5**DANGEROUS DRUGS**

sections 4, 51 and 59 of the Act

Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring

Buprenorphine

Codeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1% or less of codeine

Difenoxin except in preparations containing 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of dihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of dihydrocodeine

Diphenoxylate except in preparations containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Ethylmorphine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

SCHEDULE 5 (continued)

- (a) in divided preparations containing 100 mg or less of ethylmorphine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of ethylmorphine

Hydrocodone

Hydromorphone

Ketamine

Methadone

Methylphenidate

Moramide

Morphine

Nicocodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicocodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicocodine

Nicodicodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicodicodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicodicodine

Norcodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of norcodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of norcodeine

SCHEDULE 5 (continued)

Normethadone

Oxycodone

Pentazocine

Pethidine

Phenazocine

Phendimetrazine

Phenmetrazine

Pholcodine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of pholcodine

Racemethorphan

Racemoramide

Racemorphan

SCHEDULE 6**CONTROLLED SUBSTANCES**

sections 43A and 59 of the Act

1-Chloro-Phenyl-2-Aminopropane

1-Phenyl-2-Chloropropane

1-Phenyl-2-Methylaminopropane

1-Phenyl-2-Nitro propene

Acetic Anhydride

Benzyl Cyanide

Boron Tribromide

Ephedrine

Hydriodic Acid

Hypophosphorous acid

Phenyl Acetic Acid

Phenylpropanolamine

Phenyl-2-Propanone

Phenyl-2-Propanone Oxime

Pseudoephedrine

Pyridine

Red phosphorous

ENDNOTES

1 Index to endnotes

		Page
2	Date to which amendments incorporated	25
3	Key	25
4	Table of earlier reprints	26
5	List of legislation	26
6	List of annotations	27

2 Date to which amendments incorporated

This is the reprint date mentioned in the Reprints Act 1992, section 5(c). Accordingly, this reprint includes all amendments that commenced operation on or before 14 August 1998. Future amendments of the Drugs Misuse Regulation 1987 may be made in accordance with this reprint under the Reprints Act 1992, section 49.

3 Key

Key to abbreviations in list of legislation and annotations

AIA	=	Acts Interpretation Act 1954		prev	=	previous
amd	=	amended		(prev)	=	previously
amdt	=	amendment		proc	=	proclamation
ch	=	chapter		prov	=	provision
def	=	definition		pt	=	part
div	=	division		pubd	=	published
exp	=	expires/expired		R[X]	=	Reprint No.[X]
gaz	=	gazette		RA	=	Reprints Act 1992
hdg	=	heading		reloc	=	relocated
ins	=	inserted		renum	=	renumbered
lap	=	lapsed		rep	=	repealed
notfd	=	notified		s	=	section
o in c	=	order in council		sch	=	schedule
om	=	omitted		sdiv	=	subdivision
p	=	page		SIA	=	Statutory Instruments Act 1992
para	=	paragraph		SL	=	subordinate legislation
prec	=	preceding		sub	=	substituted
pres	=	present		unnum	=	unnumbered

4 Table of earlier reprints

TABLE OF EARLIER REPRINTS

[If a reprint number includes a roman letter, the reprint was released in unauthorised, electronic form only.]

Reprint No.	Amendments included	Reprint date
1	to reg pubd gaz 6 May 1989	23 April 1993
2	to SL No. 309 of 1996	4 December 1996
2A	to SL No. 303 of 1997	21 November 1997

5 List of legislation

Drugs Misuse Regulation 1987

made by the Administrator of the Government in Council on 29 October 1987
pubd gaz 31 October 1987 pp 836–47
commenced 31 October 1987 (see s 2)
exempted from application of SIA pt 7 (see SIA sch 2A)

Note—This regulation contains provisions relocated from the Drugs Misuse Act 1986. A list of legislation for the relocated provisions of the Drugs Misuse Act 1986 appears below.

as amended by—

regulations published gazette—

17 December 1988 pp 2214–5
commenced on date of publication

6 May 1989 pp 230–1
commenced 6 May 1989 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 1996 SL No. 309

notfd gaz 8 November 1996 pp 959–61
ss 1–2 commenced on date of notification
remaining provisions commenced 8 November 1996 (see s 2)

List of legislation to Drugs Misuse Act 1986 No. 36 schs 1–6—before relocation to Drugs Misuse Regulation 1987—

Original relocated Act

Drugs Misuse Act 1986 No. 36 schs 1–6

date of assent 5 September 1986
ss 1–2 commenced on date of assent
remaining provisions commenced 27 October 1986 (proc pubd gaz 25 October 1986 p 1242)

as amended by—

Drugs Misuse Act Amendment Act 1987 No. 53

date of assent 1 October 1987

ss 1–2 commenced on date of assent

s 10(a)(iii) commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

remaining provisions commenced 31 October 1987 (proc pubd gaz 31 October 1987 p 819)

Drugs Misuse Act Amendment Act 1989 No. 34

date of assent 28 April 1989

ss 1–2 commenced on date of assent

remaining provisions commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

Statute Law (Miscellaneous Provisions) Act 1990 No. 88 s 3 sch

date of assent 6 December 1990

commenced on date of assent

Drugs Misuse Amendment Act 1995 No. 18

date of assent 11 April 1995

ss 1–2 commenced on date of assent

s 6 commenced 8 December 1995 (1995 SL No. 358)

remaining provisions commenced 12 April 1996 (automatic commencement under AIA s 15DA(2))

Drugs Misuse Amendment Act 1996 No. 49

date of assent 15 November 1996

commenced on date of assent

List of legislation to Drugs Misuse Regulation 1987—after relocation of Drugs Misuse Act 1986 No. 36 schs 1–6

Drugs Misuse Amendment Regulation (No. 1) 1997 SL No. 303

notfd gaz 19 September 1997 pp 262–3

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 1997 SL No. 459

notfd gaz 19 December 1997 pp 1770–77

commenced on date of notification

6 List of annotations

PART 1—PRELIMINARY

pt hdg ins 1996 SL No. 309 s 4

Commencement

s 2 om R2 (see RA s 37)

Repeal

s 3 om R1 (see RA s 40)

Definitions

prov hdg sub 1996 SL No. 309 s 5(1)

s 4 def “**supply**” ins 1996 SL No. 309 s 5(3)
def “**the Act**” sub 1989 reg pubd gaz 6 May 1989 pp 230–1
om 1996 SL No. 309 s 5(2)

PART 2—SEARCH WARRANT NOTICES AND RECORD

pt hdg ins 1996 SL No. 309 s 6

Notice to justice before whom a complaint to ground a search warrant is to be sworn

s 5 amd 1996 SL No. 309 s 7

Record of proceedings

s 6 amd 1996 SL No. 309 s 8

Notice to occupier of place entered pursuant to warrant

s 7 sub reg pubd gaz 17 December 1988 pp 2214–15
amd 1996 SL No. 309 s 9

Forms

s 8 om 1996 SL No. 309 s 10

PART 3—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES

pt hdg ins 1996 SL No. 309 s 11

Prescribed procedures for the disposal of hypodermic syringes and needles

s 9 ins reg pubd gaz 6 May 1989 pp 230–1

Prescribed procedure for disposal of dangerous drugs

s 10 ins reg pubd gaz 6 May 1989 pp 230–1

PART 4—CONTROLLED SUBSTANCES

pt 4 (ss 11–15) ins 1996 SL No. 309 s 12

SCHEDULE

amd reg pubd gaz 17 December 1988 pp 2214–5
om 1996 SL No. 309 s 13

SCHEDULE 1—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 3(1)
(prev 1986 No. 36 sch 1)
amd 1996 No. 49 s 15
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 3(2)

SCHEDULE 2—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 4(1)
(prev 1986 No. 36 sch 2)
amd 1987 No. 53 s 11; 1989 No. 34 s 22; 1996 No. 49 s 16
reloc 1996 No. 49 s 21
amd 1997 SL No. 303 s 3; 1997 SL No. 459 s 4(2)–(3)

SCHEDULE 3—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 5(1)
(prev 1986 No. 36 sch 3)
amd 1987 No. 53 s 12; 1989 No. 34 s 23
sub 1990 No. 88 s 3 sch
amd 1996 No. 49 s 17
reloc 1996 No. 49 s 21
amd 1997 SL No. 303 s 4; 1997 SL No. 459 s 5(2)–(3)

SCHEDULE 4—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 6(1)
(prev 1986 No. 36 sch 4)
amd 1996 No. 49 s 18
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 6(2)

SCHEDULE 5—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 7(1)
(prev 1986 No. 36 sch 5)
amd 1987 No. 53 s 13; 1996 No. 49 s 19
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 7(2)

SCHEDULE 6—CONTROLLED SUBSTANCES

(prev 1986 No. 36 sch 6)
prev sch 6 om R1 (see RA s 40)
pres sch 6 ins 1995 No. 18 s 8
amd 1996 No. 49 s 20
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 8